Email This Article

Headlines & Perspectives
Biotech Mailbag: Study Boosts ImmunoGen
By Adam Feuerstein
10/17/08 - 11:37 AM EDT
Genentech is advancing T-DM1, which uses ImmunoGen technology, into a phase III study as a second-line treatment for Her-2 positive metastatic breast cancer.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,270.47 1,093.48 2,167.88 34.29
Oil *
75.55
UP
73.00
UP
6.24
UP
18.86
DOWN
0.17
10 Yr
3.43%
SPDR Gold
109.74
+0.72%
+0.57%
+0.88%
-0.49%
Data delayed 20 minutes

Brokerage Partners